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Abstract
Background: The safety and tolerability of sequential radioembolization-sorafenib therapy is unknown. An open-label,
single arm, investigator-initiated Phase II study (NCT0071279) was conducted at four Asia-Pacific centers to evaluate the
safety and efficacy of sequential radioembolization-sorafenib in patients with hepatocellular carcinoma (HCC) not amenable
to curative therapies.
Methods: Sorafenib (400 mg twice-daily) was initiated 14 days post-radioembolization with yttrium-90 (90Y) resin
microspheres given as a single procedure. The primary endpoints were safety and tolerability and best overall response rate
(ORR) using RECIST v1.0.Secondary endpoints included: disease control rate (complete [CR] plus partial responses [PR] and
stable disease [SD]) and overall survival (OS).
Results: Twenty-nine patients with Barcelona Clinic Liver Cancer (BCLC) stage B (38%) or C (62%) HCC received a median of
3.0 GBq (interquartile range, 1.0) 90Y-microspheres followed by sorafenib (median dose/day, 600.0 mg; median duration, 4.1
months). Twenty eight patients experienced $1 toxicity; 15 (52%) grade $3. Best ORR was 25%, including 2 (7%) CR and 5
(18%) PR, and 15 (54%) SD. Disease control was 100% and 65% in BCLC stage B and C, respectively. Two patients (7%) had
sufficient response to enable radical therapy. Median survivals for BCLC stage B and C were 20.3 and 8.6 months,
respectively.
Conclusions: This study shows the potential efficacy and manageable toxicity of sequential radioembolization-sorafenib.
Trial Registration: ClinicalTrials.gov NCT00712790.
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Introduction
Approximately 650,000 persons die each year from hepatocel-
lular carcinoma (HCC), of whom at least two-thirds live in the
Asia-Pacific region [1]. Consistent with the experience in most
Western countries, ,20% of patients within Asia-Pacific clinical
practice are diagnosed at a sufficiently early stage to benefit from
potentially curative therapies (resection, transplantation, ablation)
[2]. The remainder suffers from locally advanced or systemic
HCC and mortality from HCC continues to approximate its
incidence [1].
Radioembolization with yttrium-90 (90Y) radiolabelled micro-
spheres (also known as selective internal radiation therapy, SIRT)
significantly regresses locoregional HCC, but does not address
systemic disease [3,4]. Conversely, while sorafenib has been shown
to be an effective systemic therapy and confers a survival
advantage, tumor regression is minimal and an objective tumor
response is observed in ,5% of patients by Response Evaluation
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Criteria In Solid Tumors (RECIST) [5,6]. The addition of a
proven systemic therapy (sorafenib) to therapy that reliably
regresses locoregional tumor (radioembolization) could thereby
confer an additional survival benefit.
The theoretical benefit of combined radiotherapy and sorafenib
is supported by several preclinical studies. Radiation exposure is
thought to induce the compensatory activations of multiple
intracellular signaling pathway mediators, such as PI3K, MAPK,
JNK and NF-kB [7] as well as the up-regulation of vascular
endothelial growth factor (VEGF) [8]. It has been hypothesized
that sorafenib-mediated inhibition of the Raf/MAPK and VEGF
receptor pathways might enhance the efficacy of radiation [9].
Although the data are limited, in-vivo studies have shown that
sorafenib alters the radiation response in a schedule-dependent
manner [10]. Sorafenib administered after radiation therapy is
associated with a greater delay in tumor growth than sorafenib
pre-treatment [10,11]. The efficacy and safety of three-dimen-
sional conformal radiation therapy in augmenting the local
response to sorafenib has been reported [9]. However, these
studies are limited by the total irradiation dose that can be safely
tolerated in patients with a higher tumor burden given the
sensitivity of the normal parenchyma to radiation [12,13].
90Y-microspheres are well tolerated by patients with non-
cirrhotic livers and in those with cirrhotic livers without ascites and
in whom total bilirubin is ,2.0 mg/dL [14]. Radioembolization
may also be used in HCC patients with portal vein thrombosis, a
situation that precludes trans-arterial chemoembolization (TACE).
Radioembolization has thus developed as an alternative to TACE,
as an option in patients who are poor candidates for TACE or who
have progressive disease after having received prior TACE
[3,4,14].
The results of the Phase I study of this combination therapy
have been previously reported [15]. We report here the efficacy of
radioembolization followed by sorafenib in unresectable HCC in
the Phase II study.
Methods
Study design
This was an open-label, single arm, investigator-initiated Phase
II multicenter study conducted by the Asia-Pacific Hepatocellular
Carcinoma Trials Group. Patients were recruited from seven
tertiary medical centers in four Asia-Pacific countries (Malaysia;
Myanmar; Singapore; South Korea) with radioembolization
performed (as a single procedure) at one center (Singapore). The
study was registered with the clinical trial registry of the Health
Science Authority of Singapore (HSA) in June 2008, and
ClinicalTrials.gov (Identifier: NCT00712790) in July 2008.
The previously reported Phase I found a greater incidence of
grade 3 or 4 adverse events (mainly hand-foot syndrome) when
sorafenib was given 11 days after radioembolization (4 events in 6
patients) than after 14 days (no events in 3 patients) when
assessments were carried out for at least 30 days after commence-
ment of sorafenib [15]. These results defined the optimal duration
of 14 days between radioembolization and sorafenib treatment for
the subsequent Phase II study. All patients from the Phase I study
(recruited using the same inclusion/exclusion criteria) and treated
with sorafenib from day 14 and followed-up using the same study
design were also included in the efficacy and safety analyses for the
Phase II study.
Both studies were conducted in accordance with ISO-14155-1
(2003), the World Medical Association Declaration of Helsinki and
all applicable local regulations. Study protocol was approved by
each institute’s Human Research Ethics Committee namely, the
Centralised Institutional Review Board (CIRB), SingHealth,
Singapore; the Medical Research & Ethics Committee, Ministry
Figure 1. CONSORT diagram of Phase II trial of radioembolization followed by sequential sorafenib in patients with HCC.
doi:10.1371/journal.pone.0090909.g001
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of Health Malaysia; Institutional Review Board, Yangon GI &
Liver Centre, Yangon; and Institutional Review Board of Seoul
National University Bundang Hospital. Patients were informed of
the nature of the study and provided written informed consent.
Patients
The protocol for this trial and supporting TREND checklist are
available as supporting information (see Protocol S1 and Checklist
S1).
Patients with inoperable HCC including those with extrahepatic
disease (except CNS metastases) and/or major vascular involve-
ment (i.e. both Barcelona Clinic for Liver Cancer [BCLC] stages B
and C) were eligible for inclusion. A confirmatory diagnosis of
HCC was based on histology, or by meeting radiological criteria
for HCC by dynamic contrast-enhanced computed tomography
[CT] or magnetic resonance imaging [MRI]), with supporting
evidence based on positive serology for hepatitis B or C virus, or
serum alpha-fetoprotein above normal range ($400 mg/L)
[16,17]. All patients were $18 years of age, had measurable
disease (defined as$1 lesion of$10 mm), adequate renal function
(creatinine #2.0 mg/dL), hemopoietic function (leukocytes
$2,500/mL; neutrophils $1,500/mL; platelets $50,000/mL;








Gender, N (%) Male 7 (64) 14 (78) 21 (72)
Female 4 (36) 4 (22) 8 (28)
Ethnic group, N (%) Chinese 5 (45) 15 (83) 20 (69)
Malay 0 (0) 1 (6) 1 (3)
Indian 0 (0) 1 (6) 1 (3)
Myanmar 6 (55) 0 (0) 6 (21)
Korean 0 (0) 1 (5.6) 1 (3.4)
Age, years, mean ± SD 62.6614.8 65.867.2 64.6610.6
Prior Procedures, N (%) Total 3 (27) 4 (22) 7 (24)
Surgical resection 2{ (18) 3{ (17) 5 (17)
Ablative (RFA) 1 (9) 0 (0) 1 (3)
Vascular (TACE) 0 (0) 2 (11) 2 (7)
131I-lipiodol 0 (0) 1 (4) 1 (3)
Child-Pugh class, N (%) A 10 (91) 10 (56) 20 (69)
B 1 (9) 8 (44) 9 (31)
ECOG performance status, N (%) 0 11 (100) 11 (61) 22 (76)
1 0 (0) 7 (39) 7 (24)
Macro-vascular invasion, N (%) 0 (0) 8 (57)* 8 (32)
Extra-hepatic spread, N (%) 0 (0) 11 (61) 11 (38)
TNM stage, N (%) I 2 (18) 0 (0) 2 (7)
II 5 (45) 0 (0) 5 (17)
IIIA 4 (36) 7 (39) 11 (38)
IV 0 (0) 11 (61) 11 (38)
Total bilirubin mean, mg/dL 0.70 1.06 0.93
.1.2 mg/dL, N (%) 0 (0) 4 (22) 4 (14)
Albumin mean, g/L 31.7 30.3 30.8
,35 g/L, N (%) 3 (27) 9 (50) 12 (41)
Radioembolization: 90Y activity
administered, GBq
median (IQR) 2.0 (1.5) 3.0 (0.7) 3.0 (1.0)
Target treatment, N (%) Whole liver 7 (64) 13 (72) 20 (69)
Right lobe 4 (36) 5 (28) 9 (31)
Target tumor volume, mL median (IQR) 336 (488) 786 (1021) 484 (944)
Target liver volume, mL median (IQR) 1282 (813) 2254 (1368) 1843 (1186)
Sorafenib daily dose per patient, mg median (IQR) 600.0 (324.6) 638.8 (319.7) 600.0 (319.7)
Sorafenib treatment duration, months, median (IQR) 6.9 (7.3) 3.0 (3.9) 4.1 (4.8)
Sorafenib patients receiving .80%
planned dose, N (%)
4 (36) 7 (39) 11 (38)
* Four patients have missing information in the BCLC stage C group;
{One patient in each cohort received repeat surgical resections.
doi:10.1371/journal.pone.0090909.t001
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Table 2. Treatment-related toxicities,* stratified by time.
Overall incidence
(N=29) Post-RE and Post-sorafenib
Pre-sorafenib
(N=9) Month 1 (N=29) Month 2 (N=29) Month 3(N=27) Month 4+ (N=27)
Grade, N (%) of
patients 1–2 $3 1–2 $3 1–2 $3 1–2 $3 1–2 $3 1–2 $3
Any 13 (45) 15 (52) 4 (14) 1 (3) 12 (41) 7 (24) 6 (21) 3 (10) 5 (19) 3 (11) 10 (37) 4 (15)
Blood and lymph
Anemia 1 (3) 1 (3)
Leukopenia 1 (3) 1 (3)
Thrombocytopenia 1 (3) 1 (4)
Gastrointestinal
Abdominal distension 1 (3) 1 (3)
Ascites 1 (3) 1 (3)
Diarrhea 9 (31) 6 (21) 1 (3) 2 (8)
Nausea 2 (7) 1 (3) 1 (4)
Upper GI hemorrhage 1 (3) 1 (4)
Vomiting 3 (10) 1 (3) 3 (9) 1 (3)
General/administration site
Lethargy 1 (3) 1 (3)
Mucosal inflammation 1 (3) 1 (4)
Pyrexia 1 (3) 1 (3) 1 (3)
Hepatobiliary
Elevated ALP 1 (3) 1 (3) 1 (3) 1 (3)
Elevated ALT 1 (3) 1 (3)
Elevated AST 1 (3) 2 (7) 1 (3) 1 (3) 1 (4) 1 (4)
Hepatitis 1 (3) 1 (4) 1 (4)
Hyperbilirubinemia 3 (10) 1 (3) 1 (3) 1 (3) 1 (3) 2 (7)
Hypoalbuminemia 1 (3) 1 (3)
Infections and infestations
Sepsis 1 (3) 1 (3)
Viral infection 1 (3) 1 (3)
Injury, poisoning and
procedural complications
Fall 1 (3) 1 (4)
Radiation skin injury 1 (3) 1 (3)
Skin toxicity 1 (3) 1 (3)
Metabolism and nutrition
Decreased appetite 1 (3) 1 (3)
Renal and urinary
Urinary tract infection 1 (3) 1 (3)
Reproductive system
Scrotal pain 1 (3) 1 (3)
Respiratory, thoracic and
mediastinal
Chest discomfort 1 (3)
Hemoptysis 1 (3) 1 (3)
Pneumonia 1 (3) 1 (3)
Pneumonitis 1 (3) 1 (3){ 1 (4) 1 (4){
Skin and subcutaneous
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hemoglobin .9.5 g/dL), and Eastern Cooperative Oncology
Group (ECOG) performance status 0 or 1. In addition, eligible
patients were required to have: 1) sufficient liver function for safe
delivery of radioembolization, defined as: an absence of ascites or
synthetic liver dysfunction (total bilirubin ,2.0 mg/dL
[,34.2 mmol/L]), International Normalized Ratio (INR)#2.0;
albumin $2.5 g/dL and aspartate transaminase (AST), alanine
transaminase (ALT) and alkaline phosphatase (ALP) each #56
upper limit of normal; 2) hepatic arterial anatomy that would
enable safe delivery of microspheres to the liver only; 3) without
excess hepato-pulmonary shunting (.20%); or 4) without main
trunk portal vein thrombosis (PVT). Premenopausal, sexually-
active individuals were required to use two forms of contraception
during the study. Patients were excluded if they were pregnant or
breast feeding or had been previously treated with external beam
radiotherapy to the liver or were currently receiving any other
investigational agent.
Radioembolization
Radioembolization is a form of brachytherapy during which 90Y
microspheres are delivered via a temporary transfemoral catheter
advanced under fluoroscopic guidance into the hepatic artery
branches that supply the hepatic lesions. Pre-treatment planning
and treatment is undertaken in the angiography suite by an
interventional radiologist. Details of the procedure and post-
procedure supportive care associated with 90Y-resin microspheres
(SIR-Spheres; Sirtex Medical Limited, North Sydney, Australia)
administration have been previously described [3,18]. Prior to
treatment, eligible patients underwent CT or MRI imaging to
determine the extent of hepatic and extra-hepatic disease. A
hepatic angiography was then conducted to map the hepatic
arterial anatomy, coil embolize vessels as required, and determine
the extent of hepato-pulmonary shunting and uptake in tumor
following administration of technetium-99m macroaggregated
albumin (99mTc-MAA). Planar imaging of 99mTc-MAA was used
for treatment planning and calculating the tumor-to-normal (T:N)
ratio, with Single Photon Emission Computed Tomography
(SPECT) imaging employed in cases where further information
was needed for the accurate assessment of the extent of multifocal
disease. Radioembolization activity (in gigabecquerels [GBq]) was
calculated using the Partition Model [19], where feasible, or Body
Surface Area (BSA) method [20] when there was multifocal
Table 2. Cont.
Overall incidence
(N=29) Post-RE and Post-sorafenib
Pre-sorafenib
(N=9) Month 1 (N=29) Month 2 (N=29) Month 3(N=27) Month 4+ (N=27)
Grade, N (%) of
patients 1–2 $3 1–2 $3 1–2 $3 1–2 $3 1–2 $3 1–2 $3
Acne 1 (3) 1 (4)
Alopecia 6 (21) 2 (7) 1 (3) 3 (10)
Hand-foot syndrome 7 (24) 5 (17) 5 (17) 2 (7) 1 (3) 1 (3) 1 (4) 3 (10) 2 (7)
Rash 5 (17) 1 (3) 3 (10) 2 (7)
Vascular
Gingival bleeding 1 (3) 1 (4)
Hypertension 2 (7) 1 (4) 2 (7)
* Treatment-related toxicities included all those assessed as either definitely, probably, possibly related to treatment and unlikely to be related to treatment (excluding
only those events assessed as definitely unrelated to treatment); If a toxicity occurred multiple times to the same patient, it was counted once for that patient at the
highest grade that was assessed.Post-RE: Post-radioembolization/Pre-sorafenib period of 14 days; N =number of patients alive at each time interval; National Cancer
Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3.
Abbreviations: ALP: alkaline phosphatase; ALT: alanine transaminase; AST: aspartate aminotransferase GI: gastrintestinal.
{This was a grade 5 event.
doi:10.1371/journal.pone.0090909.t002
Table 3. Comparison of laboratory adverse events by severity from baseline to 90 days post-treatment.
N (%) patients (N=29) N (%) patients (N=29)
Pre-Treatment #90 days Post-Radioembolization
Grade 1–2 $3 1–2 $3
Total Bilirubin 2 (7) 0 14 (48) 2 (7)
Albumin 22 (76) 0 20 (69) 5 (17)
Alanine transaminase 17 (59) 0 20 (69) 1 (3)
Aspartate aminotransferase 21 (72) 1 (3) 20 (69) 8 (28)
Alkaline phosphatase 9 (31) 1 (3) 13 (45) 4 (14)
National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3; includes all events occurring up to and including 90 days post-
radioembolization.
doi:10.1371/journal.pone.0090909.t003
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disease for which discrete regions of interest could not be applied
or clearly defined. For activity calculations using the Partition
Model, the distribution of 99mTc-MAA during the simulation were
assumed to be identical to 90Y-resin microspheres, and the activity
was calculated in discrete ‘‘areas-of-interest’’ for the tumor, normal
parenchyma and lung compartments, limiting the maximum
permitted exposure for the non-tumoral liver compartment to 70
Gy [19] and lung exposure to 30 Gy. On the day of treatment,
90Y-resin microspheres were selectively infused into the affected
lobe(s) or segment(s), or whole liver via a micro-catheter placed in
the hepatic artery [14].
Sorafenib
Sorafenib (400 mg twice-daily) was initiated 14 days post-
radioembolization and then given continuously until tumor
progression or the emergence of drug-related adverse events.
Guidelines for dose adjustments and dose interruptions to
sorafenib were as per the standardized schedule reported in the
Sorafenib Hepatocellular Carcinoma Assessment Randomized
Protocol (SHARP) study [6] which required discontinuation after
two dose reductions (first to 400 mg once daily and then to
400 mg every two days).
Assessment and follow-up
Assessments were made at baseline, 2 weeks post-radioembo-
lization and thereafter at 4-weekly intervals. Baseline imaging
assessment was conducted just prior to the start of study therapy
and every 3 months or at the investigator’s discretion until disease
progression. If a complete or partial response was detected on CT,
then a confirmatory CT scan was performed between 28 and 35
days later. All responding patients were regularly assessed for
eligibility of radical therapy. Patients who progressed were assessed
at 12-weekly intervals until death or 18 months after the end of the
study. Adverse events and their severity and relationship to the
study treatment were recorded from the date of consent to 28 days
after the last dose of sorafenib. Toxicity was assessed using the
National Cancer Institute’s Common Terminology Criteria for
Adverse Events (CTCAE) version 3.0.
Endpoints and statistical analysis
The primary endpoints were both safety/tolerability and best
overall response rate (ORR), using RECIST version 1.0.
Secondary endpoints were: disease control rate (DCR), progres-
sion-free survival (PFS), overall survival (OS) and health-related
quality of life (HRQoL) using the EuroQol 5-Dimensions (EQ-5D)
Index.
Adverse events were reported from the date of radioemboliza-
tion, when sorafenib therapy started, then at monthly intervals
thereafter. If an adverse event increased in severity over the next
defined interval, it was recorded as a new event in the next
interval. PFS and OS were measured from study entry. HRQoL
was evaluated at study entry, every month during the treatment
period and at 6-month intervals thereafter [21].
The sample size for Phase II was computed using the A’Hern
single-stage design (2001) [22]. Assuming a target best ORR of
30% and a no-further-interest ORR of 10%, with type I error of
5% and power of at least 80%, a sample size of at least 25 patients
would be required. These 25 patients will include 3 to 6 already
recruited under the appropriate Phase I cohort. The study
protocol allowed for a maximum of 35 patients to be recruited,
which allows for possible lost to follow-up. A best ORR of at least
24% was required to conclude potential efficacy. Best ORR was
calculated with 95% exact confidence intervals (CI). Baseline
patient characteristics, ORR, DCR, PFS and OS were stratified
by BCLC stage to allow meaningful comparisons with other
treatment modalities. PFS and OS were summarized using the
Kaplan-Meier technique; median values and 95% CI were
reported.
A graphical plot was used to explore the pattern of HRQoL
over time. To reduce the influence of extreme values in the
graphical plot, locally weighted regression was used for smoothing
EQ-5D index [23]. A Mixed-effect model for repeated-measures
data was also performed for EQ-5D index. The model included a
patient-specific random intercept, together with the following fixed
predictors: baseline EQ-5D index; BCLC stage, and interaction
between BCLC stage and time as a continuous variable with a
linear trend. This parameterization estimates a separate intercept
and linear time trend for each BCLC stage while adjusting for the
corresponding baseline EQ-5D index. SAS version 9.2 (SAS
Institute, NC, USA) was used for all analyses.
Results
Patients
Between June 2008 and May 2009, 49 patients were assessed for
eligibility and 29 patients were enrolled (including 4 patients from
the initial Phase I study who had received sorafenib on day 14),
received radioembolization and were included in the intention-to-
treat analysis for safety (see CONSORT diagram; Figure 1).
Sorafenib was contraindicated in one patient with bleeding due to
pulmonary metastases and did not receive any further CT scans
after the baseline assessment and was excluded from the efficacy
analyses. Median follow-up was 10.9 months (range, 2.1–33.8
Figure 2. Liver function tests, stratified by time, for (A) total bilirubin, (B) albumin, (C) AST, (D) ALT and (E) alkaline phosphatase at baseline and after
radioembolization followed by sorafenib. Post-RE: Post-radioembolization/Pre-sorafenib period of 14 days.
doi:10.1371/journal.pone.0090909.g002
Table 4. Sorafenib dose modifications.
Dose modification BCLC stage B (N=11) BCLC stage C (N=17) Overall (N=28)
Dose delay, N (%) 6 (55) 10 (59) 16 (57)
Dose further delay, N (%) 0 1 (6) 1 (4)
Dose reduction, N (%) 7 (64) 4 (24) 11 (39)
Dose resumed to starting dose, N (%) 1 (9) 2 (12) 3 (11)
Dose permanently discontinued following modification, N (%) 0 1 (6) 1 (4)
doi:10.1371/journal.pone.0090909.t004
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months). Patient characteristics of 29 patients are summarized in
Table 1. Approximately two-thirds of patients had BCLC stage C
disease (62%); of whom 57% had macrovascular invasion and
61% extra-hepatic disease. Most (69%) had .25% of the liver
volume effected by tumor and/or pre-existing liver dysfunction
(41% albumin ,35 g/L; 14% total bilirubin .1.2 mg/dL); 7
(24%) had received prior liver-directed therapy (resection, RFA,
TACE or 131I-lipiodol).
Dosing
Planar and SPECT imaging were used for treatment planning
in 25 and 4 patients, respectively. The Partition Model was used
for the calculation of administered 90Y activity in all patients. The
mean T:N ratio was 4.8 (SD 6 3.5). The treatment approach
reflected the tumor burden and distribution of tumors within the
liver. Patients received a median activity of 3.0 GBq (interquartile
range [IQR], 1.0), by whole-liver (69%) and right-lobe (31%)
infusion. Median target liver and tumor volumes were 1843 mL
(IQR: 1186) and 484 mL (IQR: 994), respectively. Mean lung
shunting was 8.1%. A median of 600 mg (range, 127–791)
sorafenib was administered daily over a median of 4.1 months
(range, 0–20.4) (Table 1). The median daily sorafenib dose was
676 mg (month 1), 665 mg (month 2), 641 mg (month 3) and
566 mg thereafter. Sorafenib dose discontinuations and dose
reductions were experienced in 4% and 39% of patients overall,
and by 0% and 64% of patients with BCLC stage B, and by 6%
and 24% of patients with BCLC stage C, respectively.
Safety and tolerability
Treatment-related toxicities and mean 695% CI changes from
baseline liver function tests are presented in Tables 2 and 3, plus
Figure 2, respectively. Twenty-eight of 29 (97%) patients
experienced $1 toxicity following the treatment; 15 (52%) were
grade 3 or higher. Toxicities in 5 (17%) patients occurred post-
radioembolization and prior to sorafenib administration; all were
grade 1–2 except one grade 3 ascites.
Twenty-seven patients (93%) experienced toxicities following
sorafenib administration during month 1 (66% any grade; 24%
grade $3), month 2 (31% any grade; 10% grade $3), month 3
(30% any grade; 11% grade $3), through month 4 and beyond
(52% any grade; 15% grade $3). These toxicities resulted in
sorafenib dose reduction in 11 (39%) and discontinuation in 1 (4%)
of patients (Figure 2 and Table 4). Two patients experienced
serious disabling/incapacitating hand-foot syndrome which re-
solved with active management over 1–2 months in both cases.
The median duration of severe (n = 5; 17%) and any (n= 12; 41%)
hand-foot syndrome was 19 days and 35 days, respectively.
Diarrhea (all grade 1 or 2) was recorded in 9 (31%) patients over a
median duration of 70 days.
Two patients experienced serious liver-related adverse events
which may have been related to treatment. Both cases of serious
liver-related adverse events were secondary to disease progression
and resolved with active management over 2.5 weeks and 3
months, respectively. A third patient with abdominal extension
and symptoms of confusion and jaundice due to hyperbilirubin-
emia and infection (which may have been treatment-related) was
hospitalized, received antibiotic treatment and sorafenib treatment
was temporarily interrupted; symptoms were recorded over 4 days.
The duration of severe (grade 3+) changes in bilirubin in 2 patients
(7%) was recorded over a median of 25 days. One patient had
severe upper gastrointestinal hemorrhage at 6.3 months and 7.6
months after the initiation of sorafenib therapy which lasted 8 days
and 3 days, respectively. The duration of mild (grade 1–2)
radiation skin injury in one patient was 11 days.
One patient with progressive disease died 3 months post-
treatment due to respiratory distress attributed to therapy. The
patient had a 17% lung-shunt fraction and was administered 3.0
GBq 90Y. The pulmonary radiation exposure was 25 Gy. This
patient had an unresolved grade 2 sorafenib-related hand-foot
syndrome at 1 month post-treatment, before presenting with
respiratory symptoms at 2.5 months, whereupon sorafenib was
discontinued. The patient died two weeks later. A further patient
with a lung dose of 15 Gy was reported to have mild (grade 1)
pneumonitis 4.7 months post-radioembolization.
Response rates
Best overall response (complete response or partial response)
was observed in 7 of 28 patients (25%; 95% CI, 11–45%), which
met the pre-determined criteria of 7 responses for potential
efficacy. There were 2 (7%) complete responses, 5 (18%) partial
responses, 15 (54%) stable disease and 5 (18%) progressive disease.
The disease control rate was 79% (95% CI, 59–92%) overall, and
100% (11 of 11 cases) and 65% (11 of 17 cases) in BCLC stage B
and C, respectively. Ten (59%) of the 17 patients with BCLC stage
Table 5. Summary of efficacy measures.
BCLC stage B (N=11) BCLC stage C (N=17) Overall (N=28)
Best overall response rate, N (%) patients
Complete response (CR) 1 (9%) 1 (6%) 2 (7%)
Partial response (PR) 4 (36%) 1 (6%) 5 (18%)
Stable response (SD) 6 (55%) 9 (53%) 15 (54%)
Progressive disease 0 5 (29%) 5 (18%)
Not done 0 1 (6%) 1 (4%)
Overall response rate (CR+PR), % patients (95% CI) 46% (17–77) 12% (2–36) 25% (11–45)
Disease control rate (CR+PR+SD), % patients (95% CI) 100% (72–100) 65% (38–86) 79% (59–92)
Time to Progression, months, median, (95% CI) 15.2 (4.6–nr) 9.0 (3.5–nr) not applicable
Progression-free survival, months, median (95% CI) 15.2 (4.6–nr) 6.5 (3.5–9.1) not applicable
Overall survival, months, median (95% CI) 20.3 (10.9 nr) 8.6 (5.6–14.2) not applicable
CI: confidence interval nr: not reached.
doi:10.1371/journal.pone.0090909.t005
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Figure 3. (A) Time to progression and (B) overall survival.
doi:10.1371/journal.pone.0090909.g003
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C had extrahepatic spread; disease control beyond the liver was
not evident as assessed by RECIST 1.0.
Two patients (7%) with BCLC stage B had a sufficient tumor
response to enable radical therapy; both patients received RFA
and were censored at the time of the procedures.
Progression and overall survival
Median time to progression for BCLC stage B was 15.2 months
and 9.0 months for BCLC stage C (Table 5, Figure 3). Median
PFS for BCLC stage B and C patients were 15.2 and 6.5 months,
respectively.
Median overall survivals for BCLC stage B and C patients were
20.3 and 8.6 months, respectively.
Health-related Quality of life
Figure 4 shows the smoothed EQ-5D index using locally-
weighted regression over time in patients stratified by BCLC stage.
The evolution of patient’s EQ-5D index over time was positively
associated with their respective baseline EQ-5D index (Beta
coefficient = 0.374). EQ-5D index in BCLC Stage B decreased
over time (Beta coefficient =20.004), while it increased in BCLC
Stage C (Beta coefficient = 0.001).
Discussion
This study represents the first prospective Phase II evaluation of
sequential radioembolization-sorafenib therapy in patients from
Asia-Pacific region. The majority of patients included in this trial
had advanced HCC and a high tumor burden in the liver (median
tumor volume in the liver 448 mL), and were not ideal candidates
for TACE. The combination of radioembolization-sorafenib
appears to be manageable and consistent with previously
published experience with each treatment [6,14,24]. Excluding
hand-foot syndrome, 23% of events were grade 3 or above. Most
events were transient and managed with sorafenib dose adjust-
ments or discontinuation. By comparison, treatment-emergent
adverse events were reported in 98% of patients (including 39%
with grade 3 and 6% with grade 4 events) in the Sorafenib
Hepatocellular Carcinoma Assessment Randomized Protocol
(SHARP) study [6]. The evaluation of the combination of
doxorubicin-eluting beads (DEB) with sorafenib found that most
patients experienced at least one grade 3 to 4 toxicity, the most
common being grade 3–4 fatigue in 36% of patients, and required
dose reductions in 73% of patients [25]. By comparison, the most
commonly reported adverse event with radioembolization (in a
similar cohort of 325 patients) was fatigue occurring in 54% of
patients, including 2% with grade 3 events, with an increase in
total bilirubin reported as the most commonly reported grade 3+
event in 6% of patients at 3 months post-treatment [14].
The incentive for therapeutic intervention to palliate symptoms
or extend survival of HCC must be balanced against the degree of
hepatic functional reserve and the ability of the patient to tolerate
the procedure [26,27]. Compromised hepatic function as mani-
fested by thrombocytopenia, excessive elevations in transaminases
and bilirubin, jaundice and ascites were reported in 14% of
patients following radioembolization-sorafenib in this study. These
cases resolved upon withdrawal of sorafenib and the administra-
tion of steroid therapy.
Liver dysfunction with sorafenib is a rare event [28,29](occur-
ring in ,1% of the sorafenib-treated patients in the Asia-Pacific
trial) [5]. The risk of radioembolization-induced liver disease
(REILD) reported by Sangro et al 2008 [30] increased significantly
with high total bilirubin (.3 mg/dL), jaundice and ascites in the
absence of overt tumor progression and/or bile duct dilatation. As
advised by Lau et al 2012, the dose for uninvolved, normal
parenchyma should never be .70 Gy and should preferably
remain ,50 Gy with some institutions, especially in Asia, having
set even lower thresholds of 40–43 Gy [31]. Further study by
Figure 4. Smoothed EQ-5D quality of life index over time stratified by BCLC stage.
doi:10.1371/journal.pone.0090909.g004
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Sangro et al 2013 has shown that the frequency and severity of this
complication can be significantly reduced through modifications to
the activity calculations (which overall lowered the prescribed 90Y
activity), combined with lowering the threshold for radioemboliza-
tion from a total bilirubin of 3 to 2 mg/dL and the routine use of
ursodeoxycholic acid and low-dose steroid over the two months
post-radioembolization [32].
There was one case of thrombocytopenia which was a modest
(grade 1) event at 3.5 months post-treatment followed by patient
death due to progressive disease 2 months later. Thrombocyto-
penia has been commonly observed in HCC patients following
sorafenib administration [6] and has been rarely reported
following radioembolization [30,33,34].
Pneumonitis is an uncommon event ($1/1000 to ,1/100)
associated to sorafenib treatment [6] and is associated with
excessive lung radiation secondary to pulmonary shunting of 90Y-
microspheres [19,35]. The case of radiation pneumonitis reported
in this study was attributed to treatment and, as a result, sorafenib
was discontinued at 2.5 months post-treatment. The estimated
pulmonary radiation exposure was 25 Gy, slightly below the
recommended threshold of 30 Gy in order to mitigate the risk of
pulmonary tissue damage. The patient had no prior history of
chronic obstructive pulmonary disease that would have increased
the risk of lung tissue damage.
The nature and frequency of serious adverse events observed in
the current study are not unexpected for this population of HCC
patients with advanced disease against a background of cirrhosis,
two-thirds of whom presented with macrovascular invasion, extra-
hepatic disease and/or liver dysfunction [5,14,24]. In a European
Phase II study including a similar proportion of patients with
BCLC stage B and C, Mazzaferro et al. 2013 [27] recently
reported a 23% and 36% rate of liver decompensation at 3 and 6
months, respectively after radioembolization. While investigators
from Chicago observed that in patients with PVT, 55% of patients
decompensated from Child-Pugh A to B by the time of progression
at 5.6 months after radioembolization [26]. The one case of
possible radiation/drug-induced liver disease who expired ap-
proximately 3.5 months after commencing therapy points to the
tenuous condition that these patients often present with.
The limitations of this study are its small size and single-arm
design. There was a significant overlap between the patient
population in this study and other published studies with sorafenib
in predominantly advanced HCC, thus allowing for meaningful
comparisons. The response rate of 25.0% (including 7% with CR)
and corresponding disease control rate of 79% (by RECIST 1.0
criteria) with radioembolization-sorafenib combination is consis-
tent with experience with radioembolization alone (response rate
[40%, including 10% with CR] and disease control rate [79%] by
EASL criteria [27]) and compares favorably with the 2–9% partial
response and 35–95% disease control rate of sorafenib alone or in
combination with either conventional or drug-eluting TACE
(RECIST 1.0 criteria) [5,6,25,36]. The median overall survival of
20.3 months for BCLC stage B and 8.6 months for BCLC stage C
patients in the current study also compare favorably with the
overall survival following bland embolization in Asia-Pacific
patients with intermediate or advanced HCC (median 18.2 and
6.8 months, respectively) [37], as well as for sorafenib both in
intermediate and predominately advanced patients in the SHARP
study (median 14.5 and 9.7 months, respectively) and in the
advanced population represented in the Asia-Pacific study (median
overall survival 6.5 months; 5.6 months in those with PVT and/or
extra-hepatic disease) [5,24,38]. Selective delivery of internal
radiation therapy (proportionate to the burden and spread of
tumors in the liver) in conjunction with the anti-proliferative and
anti-angiogenic properties afforded by sorafenib may provide a
benefit greater than that afforded by either agent alone. Further
investigations are ongoing in a European multicenter randomized
Phase III study (SORAMIC: Sorafenib in combination with local
micro-therapy guided by Gd-EOB-DTPA-enhanced MRI in
patients with inoperable hepatocellular carcinoma) designed to
compare overall survival following sorafenib alone versus sequen-
tial radioembolization-sorafenib in patients with intermediate- or
advanced-stage HCC (NCT001126645). In addition, radioembo-
lization is being compared to sorafenib in two Phase III trials in
Asia-Pacific and European patients with HCC (NCT01135056;
NCT01482442).
In summary, the results of the current study provide provisional
evidence of the potential efficacy and manageable toxicity of
sorafenib and radioembolization in a population with predomi-
nantly advanced disease. Further investigation of radioemboliza-
tion and sorafenib in randomized multicenter trials are now
ongoing (NCT001126645, NCT01135056, NCT01482442,
NCT01556490) for patients with intermediate- and advanced-
stage HCC as well as for pre-transplant HCC (NCT00846131).
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